Business Description
Nektar Therapeutics
NAICS : 325412
SIC : 2834
ISIN : US6402681083
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.26 | |||||
Equity-to-Asset | 0.16 | |||||
Debt-to-Equity | 2.22 | |||||
Debt-to-EBITDA | -0.79 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -16.38 | |||||
Beneish M-Score | -1.77 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -17.9 | |||||
3-Year EBITDA Growth Rate | 16.5 | |||||
3-Year EPS without NRI Growth Rate | 30.5 | |||||
3-Year FCF Growth Rate | 17.2 | |||||
3-Year Book Growth Rate | -51.5 | |||||
Future 3-5Y EPS without NRI Growth Rate | 2.69 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 20.34 | |||||
9-Day RSI | 26.51 | |||||
14-Day RSI | 31.17 | |||||
6-1 Month Momentum % | -9.48 | |||||
12-1 Month Momentum % | 105.88 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.24 | |||||
Quick Ratio | 4.24 | |||||
Cash Ratio | 3.62 | |||||
Days Inventory | 201.1 | |||||
Days Sales Outstanding | 7.49 | |||||
Days Payable | 89.92 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2 | |||||
Shareholder Yield % | -8.2 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 67.8 | |||||
Operating Margin % | -145.91 | |||||
Net Margin % | -180.7 | |||||
FCF Margin % | -190.92 | |||||
ROE % | -154.23 | |||||
ROA % | -44.58 | |||||
ROIC % | -168.94 | |||||
ROC (Joel Greenblatt) % | -487.52 | |||||
ROCE % | -44.65 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.94 | |||||
PB Ratio | 3.4 | |||||
Price-to-Tangible-Book | 3.34 | |||||
EV-to-EBIT | -0.24 | |||||
EV-to-EBITDA | -0.25 | |||||
EV-to-Revenue | 0.38 | |||||
EV-to-Forward-Revenue | 0.31 | |||||
EV-to-FCF | -0.2 | |||||
Price-to-Median-PS-Value | 0.2 | |||||
Price-to-Net-Current-Asset-Value | 6.05 | |||||
Earnings Yield (Greenblatt) % | -416.67 | |||||
FCF Yield % | -107.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NKTR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Nektar Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 93.137 | ||
EPS (TTM) ($) | -0.84 | ||
Beta | 0.84 | ||
Volatility % | 72.11 | ||
14-Day RSI | 31.17 | ||
14-Day ATR ($) | 0.072835 | ||
20-Day SMA ($) | 1.02574 | ||
12-1 Month Momentum % | 105.88 | ||
52-Week Range ($) | 0.48 - 1.928 | ||
Shares Outstanding (Mil) | 184.46 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Nektar Therapeutics Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Nektar Therapeutics Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Nektar Therapeutics Frequently Asked Questions
What is Nektar Therapeutics(NKTR)'s stock price today?
When is next earnings date of Nektar Therapeutics(NKTR)?
Does Nektar Therapeutics(NKTR) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |